. home.aspx



Cipla taps Wellthy for digital therapeutics expertise

February 19, 2019 / Phil Taylor

Indian pharma company Cipla has made another play in the digital medicine category by taking a near-12% stake in start-up Wellthy Therapeutics. Under the terms of their agreement Wellthy and Cipla – which is India’s third-biggest pharma company – will work together on combined drug and digital therapies for type 2 diabetes as well as for patients with cardiovascular disease. Cipla is paying around 105 million rupees ($1.5 million) for its stake in Wellthy. The aim is to offer “a multi-lingual clinically-validated digital disease management platform” to patients living with these conditions via “doctors’ clinics or co-packaging on select Cipla brands.”
Wealthy's claim to fame is that it has developed India’s first prescribable digital therapeutic, a smartphone-based app that it says can help people with type 2 diabetes reduce their levels of hemoglobin A1c (HbA1c), a marker of blood sugar control over time, without the nee...